Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering
March 22, 2022 09:29 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering
March 22, 2022 07:38 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma Announces Proposed Underwritten Public Offering
March 21, 2022 16:50 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021
March 08, 2022 16:15 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform
March 07, 2022 07:30 ET
|
Statera Biopharma
In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200 FORT COLLINS, Colo., March 07, 2022 (GLOBE...
CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
March 02, 2022 09:08 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has...
Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
March 02, 2022 07:30 ET
|
Statera Biopharma
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma Announces Changes to Board of Directors
February 25, 2022 07:32 ET
|
Statera Biopharma
—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role— FORT COLLINS, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Statera...
Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21
February 22, 2022 07:51 ET
|
Statera Biopharma
FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease
February 15, 2022 09:04 ET
|
Statera Biopharma
STAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn’s Disease Phase 3 trial expected to begin in second quarter 2022 FORT COLLINS, Colo., Feb. 15, 2022 (GLOBE...